BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$27.15-2.20%
Price as of Jul 20, 2026
BCAX growth
Bicara Therapeutics Inc. Common Stock growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -51.3%
- EBIT
- -60.0%
- EPS
- -68.5%
- Free cash flow
- -32.0%
- Operating cash flow
- -31.7%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -19.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -88.9%
- Net income
- —
- EPS
- —
- Free cash flow
- -43.2%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.